Clinical trials: Dermatitis Atopic
Atopic Dermatitis
Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with…
- Trial name
- NCT06956196
- Testing
- Stapokibatrt
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Keymed Biosciences Co.Ltd
Dermatitis, Atopic
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- Liberty AD (NCT03346434)
- Testing
- Dupilumab
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 202 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Eczema
A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema
The primary objective of this study is to investigate the effect of AERODERM (also known as pitrakinra, AER 001, BAY 16-9996) on Eczema Area and Severity Index (EASI) score in subjects with moderate to severe atopic eczema
- Trial name
- NCT00676884
- Testing
- Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Aerovance, Inc.
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
- Trial name
- NCT02576938
- Testing
- Baricitinib, Triamcinolone (Optional)
- Where
- 13 sites in United States, Japan
- Volunteers
- 124 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Assessment of the Phototoxic Potential of LEO 29102 Cream
The purpose of this trial is to evaluate the phototoxic potential of a single application on healthy skin of LEO 29102 cream in different doses.
- Trial name
- NCT00958516
- Testing
- LEO 29102 cream
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Moderate-to-Severe Atopic Dermatitis
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
- Trial name
- NCT03989206
- Testing
- Nemolizumab
- Where
- 343 sites in United States, Australia and 20 more
- Volunteers
- 1,935 people
- Sponsor
- Galderma R&D
Severe Atopic Dermatitis
Verification Study of Ciclosporin for Atopic Dermatitis
To assess the efficacy and safety of oral OL27-400MEPC 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8 weeks to patients with severe adult atopic dermatitis. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
- Trial name
- NCT00232076
- Testing
- ciclosporin
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.
- Trial name
- 611 (NCT07042113)
- Testing
- new formulations of 611, existing formulations of 611
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis, Atopic Dermatitis
An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics.
- Trial name
- NCT06275659
- Testing
- CT-100-004-A, CT-100-004-B
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Click Therapeutics, Inc.
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Dermatitis, Atopic
A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis
The objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.
- Trial name
- NCT03096223
- Testing
- KHK4083
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
This is a 6-part first-in-human study in up to approximately 184 participants. Parts 1 to 5 is in health volunteers and part 6 is in subjects with atopic dermatitis.
- Trial name
- NCT03918980
- Testing
- LOU064
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD.
- Trial name
- NCT05571943
- Testing
- Difamilast
- Where
- 63 sites in United States
- Volunteers
- 542 people
- Sponsor
- Acrotech Biopharma Inc.
Atopic Dermatitis
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01639040
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 31 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects
The goal of this two-sequence, two-cycle, single and multiple-dose Phase I clinical trial is To evaluate the human bioequivalence of the test preparation and the reference preparation in 28 healthy chinese subjects at a single…
- Trial name
- NCT05945810
- Testing
- TLL-018 extended-release tablet, TLL-018 immediate-release tablet
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for…
- Trial name
- Rising Up (NCT03661138)
- Testing
- Upadacitinib, Topical Corticosteroids (TCS)
- Where
- 43 sites in Japan
- Volunteers
- 272 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with…
- Trial name
- ATLAS (NCT05155085)
- Testing
- AK002
- Where
- 55 sites in United States, Germany
- Volunteers
- 131 people
- Sponsor
- Allakos Inc.
Atopic Dermatitis
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis
The purpose of the study is to explore the efficacy and safety of SUN13834 vs placebo in adult participants with atopic dermatitis.
- Trial name
- NCT00717769
- Testing
- SUN13834
- Where
- 28 sites in United States
- Volunteers
- 270 people
- Sponsor
- Daiichi Sankyo
Atopic Dermatitis
A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.
- Trial name
- NCT05579925
- Testing
- CM310
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis (AD)
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
- Trial name
- COMPASS 2-AD (NCT07105488)
- Testing
- BFB759
- Where
- 88 sites in United States, Bulgaria and 5 more
- Volunteers
- 225 people
- Sponsor
- Bluefin Biomedicine, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.